Pharmaceutical Research

, Volume 28, Issue 4, pp 752–761 | Cite as

GFAP Promoter-Driven RNA Interference on TGF-β1 to Treat Liver Fibrosis

Research Paper



The objective was to determine the role of promoters and miRNA backbone in shRNA-based hepatic stellate cell (HSC)-specific transforming growth factor (TGF)-β1 gene silencing. This is expected to avoid the side effect of non-specific TGF-β1 gene silencing.


Two most potent shRNAs targeting 769 and 1033 start sites of rat TGF-β1 mRNA were cloned into pSilencer 1.0 vector for enhanced TGF-β1 gene silencing. We then constructed HSC-specific pri-miRNA mimic and pri-miRNA cluster mimic expression plasmids in which shRNA expression was driven by a glial fibrillary acidic protein (GFAP) promoter to achieve HSC-specific TGF-β1 gene silencing to avoid nonspecific inhibition of TGF-β1 expression in other cells and organs.


These TGF-β1 pri-miRNA-producing plasmids showed the inhibition of proliferation and induced apoptosis of activated HSC-T6 cells. TGF-β1 pri-miRNA cluster mimic plasmids decreased TGF-β1 and collagen gene expression at both mRNA and protein levels.


GFAP promoter driven TGF-β1 pri-miRNA producing plasmids have the potential to be used for site-specific gene therapeutics to treat liver fibrosis.


GFAP promoter liver fibrosis pri-miRNA mimics shRNA TGF-β1 



This study was supported by a grant from the National Institutes of Health (to RIM, grant number: EB003922).


  1. 1.
    Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134:1655–69.PubMedCrossRefGoogle Scholar
  2. 2.
    Cutroneo KR. TGF-beta-induced fibrosis and SMAD signaling: oligo decoys as natural therapeutics for inhibition of tissue fibrosis and scarring. Wound Repair Regen. 2007;15 Suppl 1:S54–60.PubMedCrossRefGoogle Scholar
  3. 3.
    Friedman SL. Liver fibrosis—from bench to bedside. J Hepatol. 2003;38 Suppl 1:S38–53.PubMedCrossRefGoogle Scholar
  4. 4.
    de Gouville AC, Boullay V, Krysa G, Pilot J, Brusq JM, Loriolle F, et al. Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis. Br J Pharmacol. 2005;145:166–77.PubMedCrossRefGoogle Scholar
  5. 5.
    George J, Roulot D, Koteliansky VE, Bissell DM. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci USA. 1999;96:12719–24.PubMedCrossRefGoogle Scholar
  6. 6.
    Kim KH, Kim HC, Hwang MY, Oh HK, Lee TS, Chang YC, et al. The antifibrotic effect of TGF-beta1 siRNAs in murine model of liver cirrhosis. Biochem Biophys Res Commun. 2006;343:1072–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Okuno M, Akita K, Moriwaki H, Kawada N, Ikeda K, Kaneda K, et al. Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta. Gastroenterology. 2001;120:1784–800.PubMedCrossRefGoogle Scholar
  8. 8.
    Qi Z, Atsuchi N, Ooshima A, Takeshita A, Ueno H. Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc Natl Acad Sci USA. 1999;96:2345–9.PubMedCrossRefGoogle Scholar
  9. 9.
    De Paula D, Bentley MV, Mahato RI. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. Rna. 2007;13:431–56.PubMedCrossRefGoogle Scholar
  10. 10.
    Cheng K, Yang N, Mahato RI. TGF-beta1 gene silencing for treating liver fibrosis. Mol Pharm. 2009;6:772–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Rumi M, Ishihara S, Aziz M, Kazumori H, Ishimura N, Yuki T, et al. RNA polymerase II mediated transcription from the polymerase III promoters in short hairpin RNA expression vector. Biochem Biophys Res Commun. 2006;339:540–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Russo FP, Alison MR, Bigger BW, Amofah E, Florou A, Amin F, et al. The bone marrow functionally contributes to liver fibrosis. Gastroenterology. 2006;130:1807–21.PubMedCrossRefGoogle Scholar
  13. 13.
    Maubach G, Lim MC, Zhang CY, Zhuo L. GFAP promoter directs lacZ expression specifically in a rat hepatic stellate cell line. World J Gastroenterol. 2006;12:723–30.PubMedGoogle Scholar
  14. 14.
    Chen SW, Chen YX, Zhang XR, Qian H, Chen WZ, Xie WF. Targeted inhibition of platelet-derived growth factor receptor-beta subunit in hepatic stellate cells ameliorates hepatic fibrosis in rats. Gene Ther. 2008;15:1424–35.PubMedCrossRefGoogle Scholar
  15. 15.
    Liu Y, Wen XM, Lui EL, Friedman SL, Cui W, Ho NP, et al. Therapeutic targeting of the PDGF and TGF-beta-signaling pathways in hepatic stellate cells by PTK787/ZK22258. Lab Invest. 2009;89:1152–60.PubMedCrossRefGoogle Scholar
  16. 16.
    Hellerbrand C, Stefanovic B, Giordano F, Burchardt ER, Brenner DA. The role of TGFbeta1 in initiating hepatic stellate cell activation in vivo. J Hepatol. 1999;30:77–87.PubMedCrossRefGoogle Scholar
  17. 17.
    Liu X, Hu H, Yin JQ. Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis. Liver Int. 2006;26:8–22.PubMedCrossRefGoogle Scholar
  18. 18.
    Doh KO, Jung HK, Moon IJ, Kang HG, Park JH, Park JG. Prevention of CCl4-induced liver cirrhosis by ribbon antisense to transforming growth factor-beta1. Int J Mol Med. 2008;21:33–9.PubMedGoogle Scholar
  19. 19.
    Synthesis, formulation and in vitro evaluation of a novel microtubule destabilizer, SMART-100. Journal of controlled release : official journal of the Controlled Release Society.Google Scholar
  20. 20.
    Liand F, Mahato RI. Bipartite vectors for co-expression of a growth factor cDNA and short hairpin RNA against an apoptotic gene. J Gene Med. 2009;11:764–71.CrossRefGoogle Scholar
  21. 21.
    Jia X, Cheng K, Mahato RI. Coexpression of vascular endothelial growth factor and interleukin-1 receptor antagonist for improved human islet survival and function. Mol Pharm. 2007;4:199–207.PubMedCrossRefGoogle Scholar
  22. 22.
    Cassiman D, Libbrecht L, Desmet V, Denef C, Roskams T. Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J Hepatol. 2002;36:200–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Ji J, Zhang J, Huang G, Qian J, Wang X, Mei S. Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation. FEBS Lett. 2009;583:759–66.PubMedCrossRefGoogle Scholar
  24. 24.
    Boudreau RL, Monteys AM, Davidson BL. Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. Rna. 2008;14:1834–44.PubMedCrossRefGoogle Scholar
  25. 25.
    Li L, Lin X, Khvorova A, Fesik SW, Shen Y. Defining the optimal parameters for hairpin-based knockdown constructs. Rna. 2007;13:1765–74.PubMedCrossRefGoogle Scholar
  26. 26.
    Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003;425:415–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science. 2004;303:83–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Han J, Lee Y, Yeom KH, Nam JW, Heo I, Rhee JK, et al. Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. Cell. 2006;125:887–901.PubMedCrossRefGoogle Scholar
  29. 29.
    Chenand G, Khalil N. TGF-beta1 increases proliferation of airway smooth muscle cells by phosphorylation of map kinases. Respir Res. 2006;7:2.CrossRefGoogle Scholar
  30. 30.
    Wu SP, Theodorescu D, Kerbel RS, Willson JK, Mulder KM, Humphrey LE, et al. TGF-beta 1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. J Cell Biol. 1992;116:187–96.PubMedCrossRefGoogle Scholar
  31. 31.
    Yan Z, Kim GY, Deng X, Friedman E. Transforming growth factor beta 1 induces proliferation in colon carcinoma cells by Ras-dependent, smad-independent down-regulation of p21cip1. J Biol Chem. 2002;277:9870–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Sun T, Adra S, Smallwood R, Holcombe M, MacNeil S. Exploring hypotheses of the actions of TGF-beta1 in epidermal wound healing using a 3D computational multiscale model of the human epidermis. PLoS ONE. 2009;4:e8515.PubMedCrossRefGoogle Scholar
  33. 33.
    Purps O, Lahme B, Gressner AM, Meindl-Beinker NM, Dooley S. Loss of TGF-beta dependent growth control during HSC transdifferentiation. Biochem Biophys Res Commun. 2007;353:841–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Lee MK, Pardoux C, Hall MC, Lee PS, Warburton D, Qing J, et al. TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J. 2007;26:3957–67.PubMedCrossRefGoogle Scholar
  35. 35.
    Saile B, Matthes N, El Armouche H, Neubauer K, Ramadori G. The bcl, NFkappaB and p53/p21WAF1 systems are involved in spontaneous apoptosis and in the anti-apoptotic effect of TGF-beta or TNF-alpha on activated hepatic stellate cells. Eur J Cell Biol. 2001;80:554–61.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Pharmaceutical SciencesUniversity of Tennessee Health Science CenterMemphisUSA

Personalised recommendations